HOOKIPA Pharma Future Growth
Future criteria checks 0/6
HOOKIPA Pharma's revenue and earnings are forecast to decline at 39.7% and 12% per annum respectively while EPS is expected to grow by 31.8% per annum.
Key information
-12.0%
Earnings growth rate
31.8%
EPS growth rate
| Biotechs earnings growth | 27.5% |
| Revenue growth rate | -39.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 20 Dec 2024 |
Recent future growth updates
Recent updates
The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 26%
Dec 21
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky
Nov 19HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues
Sep 27The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29%
Aug 13Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge
Jun 22HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth
Apr 28Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts
Mar 24Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023
Aug 11HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%
May 16Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?
Apr 26Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues
Nov 19HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy
Jul 25Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts
May 18Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1 | -44 | N/A | N/A | 1 |
| 12/31/2025 | 19 | -26 | N/A | N/A | 2 |
| 12/31/2024 | 49 | -23 | N/A | N/A | 2 |
| 9/30/2024 | 50 | -43 | -68 | -67 | N/A |
| 6/30/2024 | 52 | -49 | -77 | -74 | N/A |
| 3/31/2024 | 54 | -48 | -83 | -79 | N/A |
| 12/31/2023 | 20 | -82 | -62 | -58 | N/A |
| 9/30/2023 | 21 | -69 | -37 | -33 | N/A |
| 6/30/2023 | 16 | -68 | -28 | -26 | N/A |
| 3/31/2023 | 16 | -67 | -28 | -25 | N/A |
| 12/31/2022 | 14 | -65 | -25 | -20 | N/A |
| 9/30/2022 | 10 | -74 | -56 | -46 | N/A |
| 6/30/2022 | 12 | -76 | -59 | -48 | N/A |
| 3/31/2022 | 15 | -76 | -64 | -50 | N/A |
| 12/31/2021 | 18 | -76 | -79 | -66 | N/A |
| 9/30/2021 | 20 | -67 | -72 | -64 | N/A |
| 6/30/2021 | 20 | -60 | -63 | -57 | N/A |
| 3/31/2021 | 21 | -50 | -49 | -47 | N/A |
| 12/31/2020 | 20 | -44 | -42 | -39 | N/A |
| 9/30/2020 | 18 | -42 | -40 | -37 | N/A |
| 6/30/2020 | 16 | -40 | -39 | -36 | N/A |
| 3/31/2020 | 13 | -45 | -39 | -37 | N/A |
| 12/31/2019 | 12 | -43 | -44 | -42 | N/A |
| 9/30/2019 | 13 | -35 | -41 | -39 | N/A |
| 6/30/2019 | 13 | -27 | -38 | -37 | N/A |
| 3/31/2019 | 10 | -21 | -24 | -22 | N/A |
| 12/31/2018 | 8 | -16 | -17 | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HOOK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HOOK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HOOK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HOOK's revenue is expected to decline over the next 3 years (-39.7% per year).
High Growth Revenue: HOOK's revenue is forecast to decline over the next 3 years (-39.7% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HOOK's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:40 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HOOKIPA Pharma Inc. is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Yu He | H.C. Wainwright & Co. |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |